News
FDA approves new treatment for highly drug-resistant forms of tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received U.S. approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB
Praj signs technology cooperation agreement with Brazil’s Dedini
Praj’s scope includes technology license engineering and supply of critical equipment, whereas Dedini bears responsibility for manufacturing equipment, site supervision, customer assistance and logistics.
Boehringer Ingelheim, MD Anderson form unique Virtual R&D Center to rapidly advance new cancer therapies
The joint efforts will involve new potential gastrointestinal and lung cancer therapies from Boehringer Ingelheim’s innovative oncology pipeline will be combined with the patient-driven drug-development capabilities at MD Anderson
